Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre

Transfus Apher Sci. 2020 Apr;59(2):102658. doi: 10.1016/j.transci.2019.09.011. Epub 2019 Oct 4.

Authors

Pilar Solves¹, Susana Tur², Mario Arnao², Carmen Freiria², Lara Dominguez², M Jesús Pons², Inés Gómez³, G F Sanz³, N Carpio²

Affiliations

¹ Hospital Universitari I Politècnic la Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain. Electronic address: solves_pil@gva.es.
² Hospital Universitari I Politècnic la Fe, Valencia, Spain.
³ Hospital Universitari I Politècnic la Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, Madrid, Spain.

PMID: 31607551
DOI: 10.1016/j.transci.2019.09.011

No abstract available

Keywords: DTT; Multiple myeloma; Transfusion; anti-CD38.

MeSH terms

Aged
Antibodies, Monoclonal / pharmacology
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Blood Transfusion / methods*
Female
Humans
Male
Multiple Myeloma / drug therapy*
Multiple Myeloma / therapy*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
daratumumab